Business Standard

Monday, December 23, 2024 | 06:20 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Dr Reddy's hits 52-week high after USFDA issues EIR for Srikakulam facility

The company said, with this, all facilities under warning letter are now determined as Voluntary Action Indicated (VAI)

Dr Reddy's
Premium

The stock surpassed its previous 52-week high of Rs 4,095, touched on April 22, 2020

SI Reporter Mumbai
Shares of Dr Reddy’s Laboratories rallied 8 per cent and hit a 52-week high of Rs 4,132 on the National Stock Exchange (NSE) on Friday after the company received the Establishment Inspection Report (EIR) from US health regulator for its manufacturing plant at Srikakulam. The drug maker's stock surpassed its previous high of Rs 4,095, touched on April 22, 2020.

“The company has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA), for the Active Pharmaceutical Ingredients (API) manufacturing plant at Srikakulam, Andhra Pradesh (CTO VI), indicating closure of the audit and the inspection

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in